Skip to content
DataLookout
Menu

NCT07936162

Immune Reconstitution and Clinical Prognosis Following Umbilical Cord Blood Transplantation

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Frequency of infection-related laboratory testing (blood culture, pathogen PCR, NGS)
Timeframe: 6 months post-transplant
Number of medication adjustments intended to accelerate immune reconstitution or enhance infection prophylaxis
Timeframe: 6 months post-transplant
Number of return visits
Timeframe: 6 months post-transplant

Secondary (10)

Frequency of infection-related laboratory testing (blood culture, pathogen PCR, NGS)
Number of medication adjustments intended to accelerate immune reconstitution or enhance infection prophylaxis
Number of return visits
Immune reconstitution status (quantity of T, B, NK cells and other immune subsets, and T cell clonal diversity)
Infection rate
Show 5 moreShow less
Incidence of chronic GVHD
Relapse rate
Survival
Hospitalization rate
Outpatient rate

Arms and interventions

Composite Immune Risk Score Stratification Notification GroupExperimental

Attending physicians will receive immune reconstitution risk stratification results of patients calculated by the composite immune risk score model to guide patient health monitoring.

Standard Care Control GroupNo intervention

No risk stratification results of patients from the composite immune risk score model will be provided to attending physicians. Patients receive standard routine care.

Behavioral: Composite Immune Risk Score Stratification Notification Group

Sites

1 site in 1 country

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeTianjin, China